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Open access under tThe putrescine analogue 1,4-diamino-2-butanone (DAB) is highly toxic to various microorganisms,
including Trypanosoma cruzi. Similar to other a-aminocarbonyl metabolites, DAB exhibits pro-oxidant
properties. DAB undergoes metal-catalyzed oxidation yielding H2O2, NH4
+ ion, and a highly toxic a-oxo-
aldehyde. In vitro, DAB decreases mammalian cell viability associated with changes in redox balance.
Here, we aim to clarify the DAB pro-oxidant effects on trypomastigotes and on intracellular T. cruzi
amastigotes. DAB (0.05–5 mM) exposure in trypomastigotes, the infective stage of T. cruzi, leads to a
decline in parasite viability (IC50 c.a. 0.2 mM DAB; 4 h incubation), changes in morphology, thiol redox
imbalance, and increased TcSOD activity. Medium supplementation with catalase (2.5 lM) protects try-
pomastigotes against DAB toxicity, while host cell invasion by trypomastigotes is hampered by DAB.
Additionally, intracellular amastigotes are susceptible to DAB toxicity. Furthermore, pre-treatment with
100–500 lM buthionine sulfoximine (BSO) of LLC-MK2 potentiates DAB cytotoxicity, whereas 5 mM N-
acetyl-cysteine (NAC) protects cells from oxidative stress. Together, these data support the hypothesis
that redox imbalance contributes to DAB cytotoxicity in both T. cruzi and mammalian host cells.
 2012 Elsevier Inc. Open access under the Elsevier OA license. Introduction
a-Aminocarbonyl metabolites such as 5-aminolevulinic acid
[1,2] and aminoacetone [3,4], as well as 1,4-diamino-2-butanone
(DAB)1 [5], a large spectrum microbicide, exhibit pro-oxidant prop-
erties. These compounds were shown to undergo phosphate-cata-
lyzed enolization and subsequent aerobic oxidation propagated by
superoxide ions yielding oxyradicals and a highly cytotoxic a-oxoal-
dehyde [6], leading to oxidative damage of proteins, lipids, and DNA
[7–10].
DAB is reported to be a potent microbicide to a variety of path-
ogenic microorganisms, including Trypanosoma cruzi [11], Leish-
mania amazonensis [12], Giardia lamblia [13], Entamoeba invadens
[14], Trichomonas foetus [15] and Candida albicans [16]. The micro-, Rua Prof. Artur Riedel, 275,
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he Elsevier OA license. bicidal mechanism of DAB was ﬁrst attributed to competitive inhi-
bition of ornithine decarboxylase (ODC) [17], the key enzyme in
polyamine biosynthesis [18]. More recently, we reported that
DAB cytotoxicity in mammalian cells is related to redox imbalance
[5]. Notably, T. cruzi is susceptible to DAB toxicity [11] even though
it lacks a functional ODC gene [19].
T. cruzi is the etiological agent of Chagas disease and can be
found as free forms in the mammalian host as trypomastigotes cir-
culating in the blood, a ﬂagellate form characteristically found in
the acute phase of the disease, and as amastigotes in the cytoplasm
of the host cells, a non-ﬂagellate and dividing stage. Chagas disease
is recognized by the WHO as a neglected tropical disease, with 15–
16 million people infected in Latin America and another 75–90
million at risk of infection [20]. The current therapeutic drugs
available are benznidazole and nifurtimox, discovered more than
three decades ago, that have limited efﬁcacy for chronic treatment
and elicit undesirable side-effects [21,22]. In the past few decades,
a variety of trypanocidal compounds have been screened based on
natural or synthetic cyclic compounds with well-known biological
properties, such as antiproliferative, microbicidal or parasiticidal
activities [23,24]. More recently, metabolic biochemical pathways
and speciﬁc enzymes have been explored as targets for drug devel-
opment, including cruzipain, a cysteine proteinase, which plays a
crucial role in all stages of the parasite life cycle [25], and sterol
C14 a-demethylase (CYP51), an enzyme essential for sterol biosyn-
thesis, which is potentially inhibited by posaconazole and has
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intensive effort for the development of new drugs to treat Chagas
disease, challenges still exist due to high costs, the limited efﬁcacy
of these treatments during the chronic stage of the disease, and the
lack of practical protocols to determine a successful treatment in
humans [28,29].
We previously elucidated that the chemical mechanism of DAB
oxidation to 4-amino-2-oxobutanal (oxoDAB), a reactive a-oxoal-
dehyde, NH4+ ion, and H2O2 is mediated by oxygen- and carbon-
centered radicals [5]. Additionally, we demonstrated the molecular
mechanisms underlying the toxic, pro-oxidant effects of DAB in
mammalian cell cultures. Here, we extend these studies to clarify
the molecular bases of DAB-induced ultra-structural alterations
and death of T. cruzi in both cultured trypomastigote cells and
monkey kidney epithelial LLC-MK2 cells infected with the amasti-
gote form of T. cruzi.Materials and methods
Reagents and cell cultures
A 100 mM stock solution of 1,4-diamino-2-butanone (DAB)
(Sigma, St. Louis, MO) was prepared fresh in ultra-pure distilled
water. Stock solutions of catalase, putrescine, aminoguanidine, N-
acetylcysteine (NAC). All cell treatments were performed in phenol
red-free modiﬁed Eagle’s medium (MEM) (Vitrocell, Campinas, SP,
Brazil) supplemented with 2% fetal bovine serum (FBS) (Cultilab,
Campinas, SP, Brazil) at 37 C and in an atmosphere of 5% CO2.
LLC-MK2 cell cultures
LLC-MK2, a monkey kidney epithelial cell line, was maintained
in MEM (Invitrogen, Carlsbad, CA) supplemented with 10% FBS
(Cultilab) at 37 C and in an atmosphere of 5% CO2. For cell viability
assays, LLC-MK2 cells were seeded in a 24-well plate at a density of
5  104 cells/well 24 h prior to treatments. Cell viability was deter-
mined using the classic MTT method (Sigma) that determines
mitochondrial activity; the formazan generated was measured at
570 nm. Cell viability was expressed as percentage of formazan
generated, using the control as a reference.
Trypomastigotes
Trypomastigotes of T. cruzi (Y strain) were obtained from LLC-
MK2 cells 5–6 days post infection with the parasite, as previously
described [30]. Parasites (1  107/mL) were treated with varying
concentrations of DAB for different lengths of time. After the incu-
bations, the motility of trypomastigotes was quantiﬁed by observa-
tion under light microscopy using a Neubauer chamber. Parasite
viability was measured by a colorimetric assay using WST-1
(Roche, Indianapolis, IN) according to the manufacturer’s protocol
and expressed as the percentage of reduced WST-1, measured at
450 nm compared to the control.
To study the effects of DAB on the parasite invasion process, try-
pomastigotes (1  107/mL) were incubated with different concen-
trations of DAB for one hour in the presence or absence of 2.5 lM
catalase or 5 mM NAC in phenol red-free medium. After washing
with PBS, the parasites were resuspended in fresh medium and
added to previously seeded LLC-MK2 cells (1:100 host cell to para-
site ratio; 5  104/13 mm cover slips in 24-well plates). After 4 h
incubation, free parasites were removed bywashing the plates with
PBS and the cellswere cultured for an additional 48 h. The cellswere
then ﬁxedwith 4% paraformaldehyde (PFA) for 15 min and the pop-
ulation of intracellular parasites was estimated by randomly count-
ing nuclei stained with 20 lg/mL 40,6-diamidino-2-phenylindoledichloride (DAPI) (Invitrogen, Carlsbad, CA) using a Nikon Eclipse
E600 epiﬂuorescence microscope. At least 100 host cells were
counted per ﬁeld and 4 ﬁelds were analyzed per cover slip.
Intracellular amastigotes
To analyze the effect of DAB on intracellular amastigotes, LLC-
MK2 cultured cells (5  104/13 mm cover slips in 24well plates)
were incubated with trypomastigotes (1:100 cell to parasite ratio)
for 4 h. Free parasites were removed by washing the cell culture
with PBS and the cells transferred to fresh medium for 24 h. Under
these conditions, the infected cells contain amastigotes, the intra-
cellular stage of T. cruzi. The infected cells were then treated with
different concentrations of DAB for 6 or 24 h. Subsequently, cell cul-
tures were ﬁxed with 4% PFA for 15 min, and the amount of intra-
cellular parasites was estimated by randomly counting the nuclei
stained by 20 lg/mL DAPI (Invitrogen). At least 100 host cells were
counted per ﬁeld, and 4 ﬁelds were analyzed per cover slip.
Assay for thiols
Total thiols were estimated with monobromobimane (mBBr),
which produces a stable ﬂuorescent adduct [30,31]. The cells were
incubated with 0.8 mM mBBr in PBS for 10 min at room tempera-
ture in the absence of light. After centrifugation at 5000g for 5 min,
the cell pellet was rinsed twice with PBS and incubated with lysis
buffer (50 mM Tris at pH 8.0 containing 150 mM NaCl, 0.5% Triton
X-100 and a protease inhibitor cocktail). After 30 min at 4 C, the
material was centrifuged at 14,000g for 10 min at 4 C in an Eppen-
dorf 5417F microcentrifuge (Hamburg, Germany). The supernatant
was used to determine total thiols. The ﬂuorescence of the bimane-
adducts was measured using a SpectraMax multiwell plate reader
(Molecular Devices) at kexc = 394 nm and kem = 480 nm. Protein
concentrations were used to normalize the results.
Superoxide dismutase activity
The T. cruzi activity of superoxide dismutase (TcSOD) was deter-
mined according to the microplate method described by Ewing and
Janero [32]. Trypomastigote cell pellets were re-suspended in a
50 mM phosphate buffer at pH 7.4 containing 0.10 M EDTA and a
protease inhibitor cocktail and subjected to ultrasonic disruption
in an ice bath for 15 min. The suspension was separated by centri-
fugation at 14,000g for 10 min at 4 C. The supernatant was mixed
with a freshly prepared solution of 320 lMNBT and 100 lMNADH
in a 50 mM phosphate buffer at pH 7.4 containing 0.10 M EDTA.
The reaction was initiated by the addition of 16 lM phenazine-
metasulphate (PMS) in a pH 7.4 phosphate buffer containing
0.10 M EDTA. NBT reduction was monitored at 560 nm for 2 min
at 25 C using the SpectraMax multiwell plate reader. The activity
of SOD was expressed in units of SOD/mg protein, where one unit
is the amount of SOD required to give 50% maximal inhibition of
the initial rate of NBT reduction.
Statistical analysis
Data represent at least 3 independent experiments expressed as
means ± SD. Student’s t-test was used for statistical analysis with a
signiﬁcance level of p < 0.05.
Results
Microbicidal activity of DAB in T. cruzi trypomastigotes
DAB cytotoxicity in trypomastigotes was ﬁrst evaluated by
determining parasite motility and conducting a mitochondrial
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observed decrease in parasite motility was associated with DAB
concentration and length of incubation. After a 2 h incubation, high
concentrations of DAB (0.5 or 1.0 mM) impaired parasite motility,
which was determined by counting the number of motile parasites.
In contrast, incubation with lower concentrations of DAB (0.05 or
0.1 mM) for 4 h affected only 45% of the parasite population. Four
h incubation was chosen after a preliminary screening test to
determine the DAB IC50 for trypomastigotes (data not shown). Un-
der DAB treatment T. cruzi suffers morphological distortions and
the population of parasite round forms increases in a concentration
and time dependent fashion. The parasites were treated with dif-
ferent concentrations of DAB (0.05–5.0 mM) and viability was eval-
uated by a colorimetric assay using WST-1. As expected,Fig. 1. The motility and viability of trypomastigotes from T. cruzi exposed to DAB. Parasite
MEM supplemented with 2% FBS at 37 C and under 5% CO2. The motility was determined
of trypomastigotes was measured by a colorimetric assay using WST-1 (B).
Fig. 2. Trypomastigote TcSOD activity and thiol levels in response to DAB treatment. Para
free MEM supplemented with 2% FBS at 37 C and under 5% CO2. The total reduced thiol g
for 1 h (A). TcSOD activity was determined using the NBT/PMS method after 1 or 4 h of tre
treated samples are shown.trypomastigote viability was lessened after DAB exposure in a
dose-dependent manner, resulting in a DAB IC50 of approximately
0.2 mM (Fig. 1B). Although DAB-treated parasites lost motility in
the ﬁrst 2 h of incubation, reduction in cell viability was detected
only after longer incubations (approximately 4 h).
We further investigated the role of oxidative stress on DAB
cytotoxicity in trypomastigotes by evaluating the levels of total
thiols and activity of TcSOD (Fig. 2). The observed decline of thiols
suggests that DAB elicited changes in the parasite redox balance.
Speciﬁcally, the treatment of trypomastigotes with 0.10–1.0 mM
DAB leads to a 52% decrease of thiols after one hour incubation
(Fig. 2A). In parallel, the parasites responded to the oxidative
assault of DAB exposure by increasing TcSOD activity, which was
dependent on both DAB concentration (0.2 or 0.5 mM) ands (1  107/mL) were treated with different concentrations of DAB in phenol red-free
by direct quantiﬁcation of motile parasites using light microscopy (A). The viability
sites (1  107/mL) were treated with different concentrations of DAB in phenol red-
roups were determined by a reaction with mBBr after parasites were exposed to DAB
atment (B). Student’s t-test p-values for the comparisons between control and DAB-
Table 1
The effects of catalase, putrescine and aminoguanidine on DAB toxicity in
trypomastigotes.
Viability (%)
0.2 mM 0.5 mM
Control 54 ± 4.6 36 ± 5.6
Catalase (2.5 lM) 84 ± 7.1⁄ 76 ± 9.2⁄
Putrescine (5 mM) 60 ± 5.9 45 ± 7.7
Aminoguanidine (25 mM) 65 ± 11.1 36 ± 3.8
Parasites (1  107/mL) were incubated for 1 h with DAB in phenol red-free MEM
supplemented with 2% FBS. Viability was measured by a colorimetric assay using
WST-1. ⁄According Student’s t-test (p < 0.01), the samples are signiﬁcantly different
from control.
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the presence of catalase (2.5 lM) exerted a protective effect
against DAB toxicity (Table 1) whereas a trend for protection was
attained with putrescine (5 mM), a polyamine precursor for T. cru-
zi, or aminoguanidine (25 mM), an a-oxoaldehyde Schiff scavenger
of compounds such oxoDAB. This experiment supports the hypoth-
esis that DAB cytotoxicity may be attributed to oxidative stress.
DAB impairs host cell invasion by trypomastigotes and growth of
intracellular amastigotes
Because DAB dramatically affected trypomastigote viability and
catalase exerted partial protection, we decided to investigate
whether DAB-mediated redox imbalance in trypomastigotes could
affect host cell invasion. Trypomastigotes were incubated with dif-
ferent concentrations of DAB (0.1, 0.2 and 0.5 mM) for 1 h before
parasite addition to seeded mammalian cells. After 48 h, the infec-
tion was evaluated by measuring the population of amastigotes,
the intracellular parasite stage. A dose-dependent decrease in the
infection was observed with increasing DAB concentrations, reach-
ing 40%, 60% and 85% less amastigotes per host cell after 0.5, 0.2
and 0.1 mM DAB exposure, respectively, as compared to untreated
parasites (Fig 3A). To elucidate the oxidative role of DAB on try-
pomastigotes, reﬂected by their lower ability to invade host cells,
parasites were treated with DAB (0.2 mM) in the presence of cata-
lase (2.5 lM) or NAC (5 mM) (Fig. 3B). As expected, catalase sup-
plementation partially protected the parasites against the effects
of DAB, resulting in an approximately 25% lower infection than
that of the control and a 30% higher than DAB-treated parasites
in the absence of catalase. Conversely, NAC exhibited no protection
against DAB toxicity. Light micrographs illustrate these data
(Fig. 3C).
Additionally, the effect of DAB on the intracellular stages of T.
cruziwas studied because the internalization of T. cruzi in mamma-
lian host cells is critical for parasite survival. Cultured cells were
infected with the parasite and after 24 h were treated with differ-
ent concentrations of DAB (0.1, 0.5 and 1.0 mM) for either 6 or 24 h
(Fig. 4A). Signiﬁcant dose and time-dependent trypanocidal activ-
ity was observed after DAB treatment. For example, the number
of intracellular amastigotes was abated to 60% of the original pop-
ulation when infected cells were treated with 0.5 mMDAB for 24 h.
Although no signiﬁcant differences were observed in the amount of
intracellular parasites after the 6 or 24 h DAB-incubation, the mor-
phology of the cultured cells was signiﬁcantly altered after the 24 h
incubation. This observation was supported by the dramatic de-
crease in infected cell population and altered structure observed
in the cells treated with 1.0 mM DAB (Fig. 4B).
DAB promotes redox imbalance in epithelial cells
To conﬁrm the protective role of thiols in the cytotoxicity of
DAB in LLC-MK2 cells, GSH synthesis was inhibited using BSO, anL-glutamate analog that inhibits the synthesis of glutathionylcys-
teine, and NAC as a positive control. Pre-treatment of cell cultures
with of BSO exacerbated DAB toxicity (Table 2). The cell viability
diminished approximately 40% in the presence of BSO (100 or
500 lM) in comparison to cells treated with only DAB. As expected,
the addition of NAC mediated robust protection against DAB cyto-
toxicity, resulting in cellular viability of 90%. Additionally, the BSO
treatment resulted in signiﬁcant decrease (20%) of total thiols. Fur-
thermore, BSO treatment of cell cultures followed by DAB exposure
resulted in drastic loss of thiols; cell treated with DAB only had
approximately twice the amount of thiols. In contrast, NAC treat-
ment prevented the decrease of thiols induced by the pro-oxidant
activity of DAB (Table 2). Light micrographs revealed morphologi-
cal changes in LLC-MK2 cells caused by DAB in a dose and time-
dependent manner that were prevented by NAC supplementation
and enhanced by pre-treatment with BSO, thereby conﬁrming
the protective role of thiols in the cell redox balance (not shown).
Discussion
Oxyradicals and a-oxoaldehydes such as methylglyoxal and 4-
amino-2-oxobutanal, produced during DAB oxidation likely dam-
age lipids and proteins, disrupt mammalian cell viability and acti-
vate chemical and enzymatic cell responses against oxidative
stress [6,4,5]. DAB toxicity in several pathogenic microorganisms
was ﬁrst attributed to the competitive inhibition of ODC compro-
mising the biosynthesis of polyamines [17,15,13,12]. More re-
cently, we found that DAB causes redox imbalance in RKO cells, a
human colon carcinoma cell line, which is mediated by a more gen-
eral oxidative mechanism of toxicity (unpublished results). How-
ever, T. cruzi, which is also susceptible to DAB treatment, lacks a
functional gene for ODC [19], and Menezes et al. [11] reported
ultrastructural changes in DAB-treated epimastigotes mediated to
oxidative stress.
Here, we conﬁrm that T. cruzi trypomastigotes are highly vul-
nerable to DAB treatment (Fig. 1AB). Exposure to DAB leads to
the decrease of cell motility and viability, two parameters often
used for testing drug effectiveness [33–36], similar to DAB-treated
epimastigotes, a non-infective stage of T. cruzi present in the insect
vector [11]. Trypomastigotes exhibited up-regulation of antioxi-
dant defenses, a critical characteristic of virulence [37], and were
approximately 6 times more susceptible to DAB treatment with
an approximate IC50 of 0.2 mM after 4 h than epimastigotes with
an apparent IC50 of 1.18 mM after 3 days according to Menezes
et al. [11].
Interestingly, the trypanocidal drugs that lead to morphological
changes in the parasite [38,39] act through redox cycling systems
that yields ROS which are likely responsible for the cytotoxicity
of these compounds [38,39]. Accordingly, the DAB-mediated
depletion of thiols in epimastigotes was accompanied by an in-
crease in TcSOD activity (Fig. 2B), which represents the ﬁrst line
of antioxidant defense in T. cruzi [40]. Free thiols in T. cruzi are pro-
vided mainly by dithiol trypanothione, where two GSH molecules
are conjugated to a spermidine moiety, which are more reactive
than a single GSH molecule [41]. The crucial role of trypanothione
in the parasite oxidative stress defense is attested by the variety of
trypanothione-dependent enzymes [42]. Trypanothione is critical
for cell redox homeostasis because it delivers reducing equivalents
for synthesis of parasite deoxyribonucleotides, and performs other
oxy-reduction activities [43]. Additionally, oxidative stress trig-
gered by nifurtimox and other N-oxide-containing heterocyclic try-
panosomicides in T. cruzi is accompanied by a dramatic reduction
of low-molecular-weight thiols [42]. Interestingly, amastigotes
and trypomastigotes only contain one-third and one-half of the to-
tal thiols present in epimastigotes [22]. Furthermore, when the
parasites are exposed to high H2O2 concentrations, detoxifying en-
Fig. 3. The effects of DAB on host cell infection by T. cruzi trypomastigotes. Parasites (1  107/mL) were incubated for one hour with different concentrations of DAB in phenol
red-free MEM supplemented with 2% FBS. After washing, the parasites were resuspended in fresh medium and incubated with host cells for 4 h at cell to parasite ratio of
1:100. After 48 h, the cells were ﬁxed with 4% PFA, and the number of intracellular parasites was estimated by randomly counting the nuclei stained with DAPI (A). The
infectivity of trypomastigotes was measured after 0.2 mM DAB treatment in the presence of 2.5 lM catalase or 5 mM NAC(B). Control samples were set up as 100%, which
contain approximately two parasites per host cell. The bars represent 20 lm in Giemsa-stained infected host cells (C). According to an ANOVA, with Tukey’s test, all means are
signiﬁcantly different at a p-value of 0.05. Student’s t-test p-values for the comparisons between control and DAB-treated samples are shown.
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Additionally, TcSOD overexpression increases the resistance
against oxidative stimuli in the parasites [45]. Here, catalase pro-
vided a protective effect on DAB toxicity in trypomastigotes (Ta-
ble 1), which strongly suggests that H2O2 generated by DAB
oxidation plays important role in the oxidative injury observed in
the trypomastigotes. A similar trend was observed when mamma-
lian cells were treated with DAB in the presence of catalase [5].In this study, DAB impaired trypomastigote viability and host
cell invasion, which were prevented by the addition of catalase,
conﬁrming the role of DAB-generated H2O2 in the oxidative injury
mechanism. However, no protection was veriﬁed when the para-
sites were incubated with NAC (Fig. 3B and C). NAC is a highly per-
meable molecule that mediates redox protection in cells and can
directly act as a reductant [46] or be converted into metabolites
capable of stimulating GSH biosynthesis. During short-time incu-
Fig. 4. The effects of DAB on intracellular amastigotes. LLC-MK2 cells were incubated with trypomastigotes for 4 h using a cell to parasite ratio of 1:100 in MEM
supplemented with 2% FBS at 37 C and under 5% CO2. After 24 h, the infected host cells were treated with different concentrations of DAB for 6 or 24 h. After DAB treatment,
cell cultures were ﬁxed with 4% PFA and the amount of intracellular parasites was estimated by randomly counting nuclei stained with DAPI (A). Control samples were set up
as 100%, which contain approximately three parasites per host cell. The bars represent 20 lm in Giemsa-stained infected host cells (B). According to an ANOVA Tukey’s test,
all means are signiﬁcantly different at a p-value of 0.05. Student’s t-test p-values for the comparisons between control and DAB-treated samples are shown.
Table 2
The protective role of GSH on DAB-induced oxidative damage to LLC-MK2 cells.
1.5 mM DAB
Viability (%) Total thiols (%)
Control 58 ± 3.0¤ 59 ± 7.0¤
NAC (5 mM) 91 ± 5.4⁄ 108 ± 4.3⁄
BSO (100 lM) 18 ± 8.9¤⁄ 20 ± 9.8¤⁄
BSO (500 lM) 25 ± 5.7¤⁄ 17 ± 6.2¤⁄
LLC-MK2 cells (5  104) were pre-treated with NAC or BSO in phenol red-free MEM
supplemented with 2% FBS for 24 h at 37 C. Subsequently, cells were treated with
1.5 mM DAB and their viability evaluated after 24 h. LLC-MK2 cells (3.5  105) were
treated under the same conditions and total thiols were measured using mBBr. ¤The
means are signiﬁcantly different from respective controls in absence of DAB
(p < 0.001Student’s t-test). ⁄The means are signiﬁcantly different from control in
presence of DAB at p-value 0.01 according to Student’s t-test.
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addition, LLC-MK2 cells pre-treatment with 5 mMNAC for 24 h fol-
lowed by DAB exposure resulted in substantial maintenance of via-
bility (Table 2). However, NAC has been reported to both protect
host cells from parasite infection [47] and improve the parasite
ability to invade host cells [48]. Therefore, NAC might boost the
antioxidant response in both host and parasite cells, thus improv-
ing host cell protection against parasite infection while concur-
rently allowing parasites to evade the host cell defense
mechanisms.
Recently, Soares et al. [5] reported an approximate IC50 = 1.5 -
mM for DAB in LLC-MK2 epithelial cell line, which is about 7 times
higher than the IC50 determined for T. cruzi trypomastigotes in this
study (Fig. 1B). DAB was also observed to induce redox imbalance
Fig. 5. Proposed mechanism for DAB cytotoxicity to Trypanosoma cruzi and mammalian host cell. DAB undergoes metal-catalyzed aerobic oxidation yielding ROS, ammonium
ion, an intermediate a-oxoaldehyde (oxoDAB) [Error! Bookmark not deﬁned.]. This reaction takes place mainly in the extracellular environment, resulting in redox imbalance
of both LLC-MK2 cells and T. cruzi cells.
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ingly, pre-treatment of cells with BSO aiming to inhibit the synthe-
sis of GSH resulted in a considerable increase of DAB cytotoxicity
(Table 2). Cellular changes in the redox state of thiol pools are
known to reﬂect oxidative assault [49]. Considering the features
of parasites and mammalian host cells stress defenses [44], several
authors [50,51] investigated the potential synergistic effects of BSO
with nifurtimox and benznidazole at different life stages of T. cruzi,
and concluded that BSO potentiates the effects of these drugs in
the trypomastigote and amastigote forms.
Finally, DAB treatment of epithelial cells infected with T. cruzi
leads to a signiﬁcant dose- and time-dependent attenuation of
intracellular parasites (Fig. 4A and B). Similar results were reported
using L. amazonensis-infected macrophages treated with DAB [12].
The inhibitory effect of DAB on the proliferation of intracellular
amastigotes may be related to the impairment of nutrients sus-
tained by the pool of thiols, as observed here when LLC-MK2 cells
were treated with DAB (Table. 2). Indeed, it is well known that oxi-
dative stress triggers antioxidant responses that may consume the
cellular stock reserves [52]. DAB displayed notable deleterious ef-
fects on both intracellular T. cruzi amastigotes and host cells, espe-
cially at high concentrations (Fig. 4B). This is a frequent outcome in
the search for new therapeutic drugs that act on a variety of para-
sites. Signiﬁcant lethal effects in free parasites and host cells often
appear in parallel when testing new drugs [38,53,54].
In conclusion, as sketched in Fig. 5, DAB efﬁciently decreases
trypomastigote viability and T. cruzi infection of host mammalian
cells probably by mechanisms linked to oxidative stress, however
DAB displays signiﬁcant lethal effects to host cells as well.Acknowledgments
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